Aventis's MyDocOnline buys certain Internet assets from Andrx
As part of these transactions, Andrx said it expects to receive approximately $6 million over the next two years.
By on Aug 6, 2002As part of these transactions, Andrx said it expects to receive approximately $6 million over the next two years.
Dr. Chart is an application designed to allow for electronic transmission of lab results over the Internet, and @Rx is an electronic prescription writer. In connection with @Rx, Andrx granted Aventis a non-exclusive license to Andrx's U.S. patent numbers 5,737,539 and 5,845,255, related to the electronic transmission of prescriptions over the Internet.
"We continue to see the value of Internet access to physicians as an element for the marketing of branded pharmaceutical products and services, said Richard Lane, Andrx's CEO. Today's announcement demonstrates a major international pharmaceutical company's belief in Internet access to physicians and the value that our POL offers. Our divestiture of non-core Internet assets coupled with a marketing agreement with a major pharmaceutical player is yet another step in optimizing our Internet strategy and assets. In the interest of long term shareholder value, we will continue to evaluate our Internet assets and strategies within Andrx and its evolution toward a brand company, including evaluating additional Internet divestitures and alliances."